FOLKS FIRSTLY, Congratulations on the trading plays re BPO...

FOLKS FIRSTLY, Congratulations on the trading plays re BPO today, well done. I myself could not wait to offload at just over 10 cents. They went to 3.8 not long ago.

Be very wary of these burglars. I have been playing BPO since 2001 and made both profit and loss. One of my most memorable losses was when I bought at 20 cents and sold at 15. I think it got to 22-24 at one stage.

These guys are the master of spin, the termite product is recycled from september 2003 and their latest attempt so they can do another placement, they are strapped for cash.

They have deleted important announcements from their website re 2001 -2002 because of failure. If you intend to trade them fine, worth a risk, but hold long term at your peril. If you do intend to hold ask the big cheese Selwyn Snell about when they expect to make any money have any products? Also ask him about Qcide, and Japan deals, hepatitis with apath and the prostate cancer neutracel deal with Lane laboratories in the US(that was a pearler from 2001 that caught me). Not to mention the company bought to produce stuff that was a dud.

Here is some examples of their spin.. A couple of emails to me from them in 2002, 2003.. I have more up my sleeve
Sent: Thursday, April 18, 2002 1:39 PM
Subject: Re: BioProspect Australia Limited


> Dear !!!!!!!!!,
>
> In answer to your recent inquiries, we are expecting our Prostate cancer
> product PC-OZ to be launched on time and we are currently waiting on our
> partner's instructions on the launch announcement.
>
> We are also in negotiation on the evaluation of Qcide and hope to have this
> finalized soon for announcement approximately by mid May.
>
> Thank you for your interest in our company.
>
> Sincerely
> Melanie Marcolina

Sent: Thursday, January 23, 2003 12:12 PM


Please find attached Media Release made by the Company today regarding our collaboration with Apath LLC of the United States. The collaboration will seek to discover novel compounds that will focus on uncovering a cure for Hepatitis C Virus (HCV) and other human viral pathogens.



HCV is a virus that afflicts an estimated 170 million individuals worldwide and the market for HCV therapeutics is expected to grow to US$5 billion by 2010.



This agreement signifies further acceptance from the drug discovery world of BioProspect’s unique Natural Plant Extract library and the revenues received will further underpin the business’ operating costs.



Please do not hesitate to contact me should you require any further information.



Yours sincerely,

BioProspect Limited



Selwyn Snell

CEO


Masters of spin
Play them & trade them but don't get caught holding, good luck all.

cheers